On June 23, 2023 Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto) reported that the company has received approval from the Ministry of Health, Labour and Welfare ("MHLW") for partial change of its antineoplastic mitomycin C agents (Mitomycin Injection 2 mg and Mitomycin Injection 10 mg) for the purpose of changing to a manufactured product in-licensed from Intas Pharmaceuticals Ltd. (Intas) (Press release, Kyowa Hakko Kirin, JUN 23, 2023, View Source [SID1234632875]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kyowa Kirin voluntarily recalled its mitomycin C agent from October 2019 due to the discovery of facts that could affect the assurance of sterility in the API manufacturing process. Since then, Kyowa Kirin has been taking all possible actions to resume the supply of this product. In September 2022, Kyowa Kirin submitted an application to seek approval of Intaslicensed mitomycin C agent for use as an antineoplastic agent in Japan. Currently, the supply is under preparation and will be started when it is ready.

Apart from above, the topical ophthalmic mitomycin C agent (MITOMYCIN 2 mg for Ophthalmic Topical Use) had been approved by MHLW on December 23, 2022 and has been listed on the NHI (National Health Insurance) drug price list on May 24, 2023. Currently Kyowa Kirin is making preparation for its launch.

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.